ASEP Medical Holdings Inc (ASEP) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): -1.10
• Revenue Growth: 21.67%
• EPS Growth: -53.47%
• Country: CA
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 11,123,729
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: -0.05
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 603.52
• P/FCF Ratio: -4.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 31 Underperform
• Price Target: ―

ASEP Medical Holdings Inc exhibits substantial financial difficulties, with ongoing losses and negative cash flows weighing heavily on its overall score. The technical indicators suggest a negative market sentiment, with the stock trading below key moving averages. Valuation is poor due to negative earnings and lack of dividends, emphasizing the company's current unprofitability. Without notable improvements or strategic initiatives to enhance revenue and profitability, the stock remains a high-risk investment.

Positive Factors

Low Financial Leverage

Low financial leverage suggests ASEP has a conservative capital structure, which may provide stability and reduce financial risk in the long term.

Innovative Product Development

A strong focus on R&D can lead to innovative products that address unmet medical needs, potentially driving future growth and competitive advantage.

Strategic Partnerships

Strategic partnerships can enhance ASEP's market presence and product portfolio, facilitating revenue growth and long-term business sustainability.

Negative Factors

Negative Cash Flow

Negative cash flow indicates ASEP struggles to generate sufficient cash from its core operations, potentially impacting its ability to fund growth and meet obligations.

Persistent Losses

Ongoing losses highlight ASEP's struggle with profitability, which could threaten its financial health and ability to invest in future growth.

Negative Profit Margins

Negative profit margins suggest ASEP is not efficiently converting revenues into profits, indicating operational inefficiencies that may hinder long-term success.

ASEP Medical Holdings Inc Business Overview & Revenue Model

Company Description

Asep Medical Holdings Inc., through its subsidiary, ASEP Medical Inc. focuses on developing an early diagnostic tool for Sepsis and peptide therapeutic treatments for multiple applications. The company was formerly known as Trenchant Life Sciences Investment Corp. and changed its name to Asep Medical Holdings Inc. Asep Medical Holdings Inc. was incorporated in 2020 and is headquartered in Vancouver, Canada.

How the Company Makes Money

ASEP Medical Holdings Inc generates revenue through the development and commercialization of its proprietary medical technologies and solutions. The company earns money by licensing its innovations to pharmaceutical companies, healthcare providers, and medical device manufacturers. ASEP may also engage in strategic partnerships and collaborations to enhance its product offerings and expand its market reach. Additional revenue streams could include sales of its developed products, royalties from licensed technologies, and potentially government or private sector grants for research and development initiatives.

ASEP Medical Holdings Inc Financial Statement Overview

Summary

ASEP Medical Holdings Inc faces significant financial challenges with persistent losses and negative cash flows. While leverage is low, the company struggles with profitability and cash generation, which could hinder long-term sustainability. Strategic improvements in revenue generation and cost management are necessary to enhance financial health.

Income Statement

ASEP Medical Holdings Inc has shown minimal revenue growth with significant net losses over the years. The TTM (Trailing-Twelve-Months) Net Profit Margin and Gross Profit Margin are both negative, indicating a lack of profitability. Revenue growth is present but from a low base, and EBIT and EBITDA margins are also negative, suggesting ongoing operational challenges.

Balance Sheet

The balance sheet shows a modest debt-to-equity ratio, indicating low financial leverage, which is a positive aspect. However, the company has been consistently reporting negative equity in prior years, highlighting potential financial instability. The Equity Ratio is moderate but has shown a declining trend, raising concerns about asset management.

Cash Flow

Operating cash flow remains negative, reflecting challenges in generating cash from operations. Free cash flow has improved slightly in the TTM period but remains negative. The company's reliance on financing activities to support its cash flows suggests potential liquidity issues.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	243.92K	21.14K	0.00	0.00	0.00	61.17K
Gross Profit	-232.37K	-113.74K	-155.40K	-177.18K	-26.45K	6.16K
EBITDA	-4.17M	-8.14M	-4.56M	-2.06M	0.00	0.00
Net Income	-4.64M	-8.23M	-5.76M	-2.30M	-28.10K	-353.00
Balance Sheet
Total Assets	24.30M	25.61M	27.08M	30.72M	10.98K	2.59K
Cash, Cash Equivalents and Short-Term Investments	12.28K	64.72K	2.13M	5.29M	8.47K	534.00
Total Debt	22.17K	20.00K	0.00	0.00	140.71K	110.66K
Total Liabilities	4.42M	3.05M	528.16K	144.20K	161.51K	125.03K
Stockholders Equity	10.55M	12.61M	15.47M	18.26M	-150.53K	-122.43K
Cash Flow
Free Cash Flow	-1.11M	-2.72M	-3.61M	-1.31M	-22.12K	-47.96K
Operating Cash Flow	-1.11M	-2.71M	-3.61M	-1.19M	-22.12K	-47.96K
Investing Cash Flow	-1.25K	-4.47K	124.80K	146.08K	0.00	0.00
Financing Cash Flow	862.26K	651.40K	330.00K	6.34M	30.06K	47.54K

ASEP Medical Holdings Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASEP, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.43, and below the 200-day MA of 0.49, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 32.64 is Neutral, neither overbought nor oversold. The STOCH value of 38.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ASEP.

ASEP Medical Holdings Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NSHS	47 Neutral	C$256.88K	0.65	8.55%	―	―	―
ASEP	31 Underperform	―	-0.21	-96.25%	―	21.67%	-53.47%
CHGX	24 Underperform	C$415.65K	-0.53	21.10%	―	―	―
WBIO	22 Underperform	C$324.76K	-38.89	1.08%	―	―	―

ASEP Medical Holdings Inc Corporate Events

Asep Medical Resumes Trading After Revocation of Cease Trade Order

Asep Medical Holdings Inc. announced the revocation of a Failure-to-File Cease Trade Order by the BC Securities Commission, which had been imposed due to a delay in filing annual financial statements. The revocation allows the company to resume normal trading activities and continue advancing its strategic initiatives, including the development of its Sepsis Diagnostic and Anti-Biofilm Peptide Technology Platforms. This development underscores the company’s commitment to strong corporate governance and timely financial reporting, while maintaining the support of its shareholders and stakeholders.

Asep Medical Holdings Updates Year-End Management Discussion and Analysis

Asep Medical Holdings Inc. has amended and refiled its Management’s Discussion and Analysis for the year ended December 31, 2024. The amendments include new disclosures on the company’s intellectual properties and research and development activities, particularly focusing on its subsidiaries’ therapeutic and diagnostic technologies. These updates aim to provide enhanced transparency regarding the company’s operations and governance, potentially impacting its market positioning and attractiveness to investors.

Asep Medical Licenses Anti-Biofilm Technology to Bondent for Oral Rinse in China

Asep Medical Holdings Inc. has entered into a Patent Licensing Agreement with Shanghai Bondent Technology Co., Ltd. to develop and commercialize an oral rinse using Asep’s anti-biofilm peptide technology in China and other key markets. This collaboration marks a significant step in Asep’s strategy to introduce novel anti-biofilm solutions to the global dental market, potentially setting a new standard of care for oral health. Additionally, Timothy Murphy, the company’s former COO, will transition to a leadership role at Sepset Biosciences Inc., focusing on the commercialization of a sepsis diagnostic technology, aligning with Asep’s strategic priorities in infectious disease diagnostics.